South County Urological logo in color

“Unprecented,” Says Lead Author Of Study Investigational Prostate Drug

New drug shows promise in treating metastatic prostate cancer.

A new drug demonstrated “unprecedented” benefit in treating prostate cancer that metastasized or spread to the bones, according to a study written by University of Michigan Comprehensive Cancer Center researchers. The drug  — cabozantinib — helped shrink bone metastases and decrease pain in men participating in the study.  Dr. David C. Smith, professor of internal medicine and urology at the university, was lead author.

The phase II trial enrolled 171 men whose prostate cancer no longer responded to hormone-based therapy. About two-thirds of the patients treated with cabozantinib saw improvements on their bones scans, and 56 percent decreased or eliminated their use of narcotic painkillers.  More trials are underway to better understand the drug’s potential role in prostate cancer treatment.

Results of the study appeared in the Journal of Clinical Oncology.

Specializations Include...

Blog Topics

Blog Updates

Set your categories menu in Header builder -> Mobile -> Mobile menu element -> Show/Hide -> Choose menu
Shopping cart
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Start typing to see posts you are looking for.